Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Zanidatamab
Related studies linked through entity extraction aliases.
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
- Status
- RECRUITING
- Phase
- PHASE2
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
- Status
- RECRUITING
- Phase
- PHASE2
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Personalized Medicine for Advanced Biliary Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2